Company Snapshot: NABI  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Nabi Biopharmaceuticals to Announce 2006 Fourth Quarter and Year-End Financial Results on February 28, 2007

              Annual Shareholders Meeting Set for May 18, 2007

    BOCA RATON, Fla., Feb. 6 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) will announce 2006 fourth quarter and
year-end financial results on Wednesday, February 28, 2007, after market
close. The company will also host a live webcast at 4:30 p.m. ET.
    The live webcast can be accessed at http://phx.corporate-
ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=1473397 or via
the Nabi Biopharmaceuticals website at http://www.nabi.com. If you do not
have Internet access, the U.S./Canada call-in number is 866-713-8310
conference code 57672232, and the international call-in number is
617-597-5308 conference code 57672232. An audio replay will be available
for U.S./Canada callers at 888-286-8010 conference code 51818152, and for
international callers at 617- 801-6888 conference code 51818152.
    An archived version of the webcast will be available at the same
Internet address through March 7, 2007. The audio replay will also be
available through March 7, 2007. The press release will be available on the
company's website at http://www.nabi.com.
    Nabi Biopharmaceuticals also announced today that its Annual Meeting of
Shareholders will be held on Friday, May 18, 2007, in Boca Raton, Florida,
at 10:00 a.m. ET at the Renaissance Boca Raton Hotel, Coral Ballrooms B, C
and D, 2000 NW 19th Street, Boca Raton, Florida, (561) 368-5252.
    About Nabi Biopharmaceuticals
    Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has two products on the market
today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM)
(allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on
developing products that address unmet medical needs and offer commercial
opportunities in our core business areas: Hepatitis and transplant,
Gram-positive bacterial infections and nicotine addiction. For a complete
list of pipeline products, please go to:
http://www.nabi.com/pipeline/index.php. The company is headquartered in
Boca Raton, Florida. For additional information about Nabi
Biopharmaceuticals, please visit our website: http://www.nabi.com.


SOURCE Nabi Biopharmaceuticals




Back to Topback to top

Related links:
  • http://www.nabi.com/
    CONTACT:
    Thomas E. Rathjen, Vice President, Investor
    Relations of Nabi Biopharmaceuticals, +1-561-989-5800